3-MMC
3-MMC (metaphedrone) is a synthetic cathinone stimulant closely related to mephedrone, which it largely replaced after mephedrone was banned. It acts on dopamine, norepinephrine, and serotonin, produces short-acting stimulant and mild empathogenic effects, and carries a high risk of compulsive redosing and dependence.
Overview
3-MMC (3-methylmethcathinone, also called metaphedrone) is a synthetic cathinone stimulant and a close chemical relative of mephedrone (4-MMC), differing only in the position of one methyl group on the molecule. It emerged on the European drug market around 2012, largely as a replacement for mephedrone after that drug was banned, and its use grew in the following years. It is usually found as a powder or in tablets, capsules, or occasionally liquids, and is typically swallowed or snorted; it is also used in "chemsex" settings, sometimes by injection. It has been assessed at the European level and brought under control across the EU.
Source: EUDA/EMCDDA risk assessment; WHO ECDD review
Chemistry & mechanism of action
Like its relative mephedrone, 3-MMC acts on the brain's monoamine systems: laboratory studies indicate it inhibits the reuptake of dopamine, norepinephrine, and serotonin, raising their levels in the brain. Its overall profile is described as more amphetamine-like than MDMA-like — that is, weighted toward dopamine-driven stimulation more than serotonin-driven empathy — which, combined with its short duration of action, helps explain the strong drive to redose that users and regulators have flagged. A first-in-human study of low-to-moderate doses (25-100 mg) found dose-dependent rises in heart rate and blood pressure and a subjective "high," consistent with a stimulant structurally related to amphetamine.
Source: EUDA/EMCDDA risk assessment; peer-reviewed pharmacology literature
Effects
3-MMC produces stimulant effects — increased energy, alertness, euphoria, talkativeness, and sociability — along with mild feelings of closeness, giving it a milder empathogenic edge on top of a mainly amphetamine-like profile. Onset is fairly rapid and the effects are short-lived, which strongly encourages repeated dosing within a session. Common unwanted effects include raised heart rate and blood pressure, jaw clenching, restlessness, reduced appetite, and difficulty sleeping.
Source: EUDA/EMCDDA risk assessment; peer-reviewed pharmacology literature
Risks & harms
The clearest risks with 3-MMC are compulsive redosing and dependence: its short duration and strong dopamine action drive bingeing, which regulators specifically flagged as a concern. The European risk assessment reviewed cases of acute poisoning, several of them life-threatening, and its acute toxicity and abuse potential are considered comparable to other controlled synthetic cathinones. Heavy use is associated with anxiety, paranoia, and psychosis. Most reported deaths involved 3-MMC together with other drugs. Use in chemsex or "slamsex" settings adds further risks: overdose via injection, injection-site infections, and increased exposure to blood-borne viruses such as HIV and hepatitis C. As with other cathinone powders, contents and strength vary between samples.
Source: EUDA/EMCDDA risk assessment; WHO ECDD review
Legal status (US)
3-MMC was brought under control across the European Union in March 2022 following a formal EMCDDA/EUDA risk assessment, and it has been scheduled in a number of individual countries as well. Legal status varies by jurisdiction and can change; local law is what applies to you.
Source: EUDA/EMCDDA risk assessment
Drug laws and enforcement change and vary by country. This is not legal advice. Always confirm with the destination’s embassy or official drug authority before traveling, because penalties can be severe, including imprisonment.
Before you travel
Verify current rules with the destination country’s official drug authority and your own country’s embassy before traveling. Find the destination’s U.S. embassy & official country guidance →
Non-U.S. travelers: check your own government’s travel advisory and embassy.
If you’re detained or arrested abroad
Contact your own country’s embassy or consulate in the destination immediately, not the destination’s authorities. U.S. citizens: contact the nearest U.S. embassy/consulate and the U.S. State Department at +1-202-501-4444 (from abroad). If a U.S. citizen is arrested or detained abroad →
Images
Visual references coming soon.
If it’s too intense
If an experience becomes overwhelming, the goal is to stay safe and let it pass, most difficult experiences ease as the drug wears off.
- Get to a calm, safe space with someone you trust who is sober and can stay with you.
- Cool down if you’re overheating, move somewhere cool, remove extra layers, rest. Overheating is especially a risk with stimulants and MDMA.
- Sip water to thirst, but don’t over-hydrate. Drinking large amounts of plain water (especially after MDMA) can dangerously dilute your blood sodium (hyponatremia). Electrolytes help more than volume.
- Slow your breathing, long, slow exhales help settle a racing heart and anxiety.
- A sugary drink, fruit juice, or a snack can ease shakiness and the anxiety that comes with low blood sugar.
- Do not take more, and do not add another substance to manage it. Redosing or adding something else (including a sedative like a benzodiazepine) can make things worse, not better.
After MDMA, overheating and over-hydration are both dangerous: cool down, and sip to thirst rather than gulping water (forcing plain water can drop your blood sodium dangerously).
Source: general harm-reduction guidance from SAMHSA, NIH/NIDA, and MedlinePlus, in our own words. Draft, not yet medically reviewed.
Forensic dossier
Draft · every field is source-cited or marked “Unknown, pending review”Identity
- PubChem CID
- 71741532PubChem PUG-REST ↗ · retrieved 2026-06-18
- IUPAC name
- 2-(methylamino)-1-(3-methylphenyl)propan-1-onePubChem PUG-REST ↗ · retrieved 2026-06-18
- Molecular formula
- C11H15NOPubChem PUG-REST ↗ · retrieved 2026-06-18
- SMILES
- CC1=CC(=CC=C1)C(=O)C(C)NCPubChem PUG-REST ↗ · retrieved 2026-06-18
- InChIKey
- QDNXSIYWHYGMCD-UHFFFAOYSA-NPubChem PUG-REST ↗ · retrieved 2026-06-18
- Synonyms / aliases
- metaphedrone, 3-Methylmethcathinone, 3-MMC compound, 3-methylmethcathinone (3-MMC), QDNXSIYWHYGMCD-UHFFFAOYSA-NPubChem PUG-REST + seed aliases ↗ · retrieved 2026-06-18
Composition
- Composition
- N/A — single compound (see Identity)
Physical / pill characteristics
- Dosage form
- Unknown — pending review (no Rx/OTC label; illicit — pill visuals = FIRST-PARTY submissions only, never generated or scraped)
- Route
- Unknown — pending review
- Shape
- Unknown — pending review
- Color
- Unknown — pending review
- Imprint
- Unknown — pending review
- Score
- Unknown — pending review
Scheduling & legal status
- US schedule
- Unknown — pending review
- International
- Unknown, pending review
Effects, risks & interactions
- Effects
- 3-MMC is a synthetic cathinone very close to mephedrone (4-MMC) — a positional isomer of it — which came to prominence as a "successor" after mephedrone was banned in many countries. Its effects are broadly similar: a stimulant-empathogen mixture of euphoria, energy, sociability and warmth, with the same brief, redose-prompting profile. It is a later-wave "research chemical" that filled the gap left by earlier prohibitions.NIDA Synthetic Cathinones (Bath Salts) + PubChem CID 71741532 ↗ · retrieved 2026-06-18
- Risks
- 3-MMC brings the cathinone-class dangers: brief effects that prompt compulsive redosing, stacking a heavy sympathomimetic burden — elevated pulse and blood pressure, chest pain, overheating — and, through serotonin release, a risk of serotonin toxicity when taken with other serotonergic drugs. Anxiety, agitation and sleeplessness are common with heavier use. Because this is a substance that exists precisely to stay one step ahead of drug laws, it is produced with no quality control and shifting composition, so its strength and identity are unknown to whoever buys it — the central harm-reduction risk.NIDA Synthetic Cathinones (Bath Salts) + PubChem CID 71741532 ↗ · retrieved 2026-06-18
- Interactions
- Unknown, pending review
Dosage
Pending medical reviewer
